Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Vividion’s ‘Unique’ Platform Draws $82M Series B Round.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): WHITLOCK, JARED
- Source:
San Diego Business Journal. 5/6/2019, Vol. 40 Issue 18, p4-4. 1p.
- Subject Terms:
- Additional Information
- Subject Terms:
- Subject Terms:
- Abstract:
The article informs that Vividion Therapeutics that has formed to transform drug development by targeting "undruggable" proteins has attracted a Series B round funding. It mentions that the firm has lead programs in oncology and immunology. It presents views of Diego Miralles, chief executive officer at Vividion Therapeutics on drug development.
No Comments.